Tuesday, 07 Apr 2020

You are here

Number of Prior DMARDs Portends Poorer Outcomes

Detailed analysis of two clinical trials in rheumatoid arthritis (RA) has shown that clinical responses decrease as the disease duration and number of prior disease-modifying antirheumatic drugs (DMARDs) increase.

The associations between disease duration and number of prior DMARDs and response to therapy were assessed using data from two randomised controlled trials in patients with established RA (mean duration, 11 years) receiving adalimumab+methotrexate.

Clinical efficacy responses were assessed at week 24 using standard disease activity outcomes.

Both trials demonstrated that a greater number of prior DMARDs and longer RA duration were associated with lower ACR response rates at week 24.

In one trial of 207 RA patients showed when comparing a many to few prior DMARDs (>2 vs 0–1) there was smaller improvements by week 24 in:

  • DAS28(CRP) (–1.8 vs –2.2)
  • SDAI (–22.1 vs –26.9)
  • HAQ-DI (–0.43 vs –0.64)\.

When comparing disease duration (>10 years versus <1 year) higher HAQ-DI scores (1.1 vs 0.7) were seen at week 24, but results on DAS28(CRP) and SDAI were mixed.

Number of prior DMARDs, moreso than disease duration, appears to identify refractory RA patients who may not respond as well to future treatment interventions.

The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Need for Disruptive Innovation in Rheumatology

A full-read, novel Viewpoint article published in the Annals of Rheumatic Disease (Huizinga TWJ, et al) spotlights a recent international meeting of big thinkers, scientific collaborators and industry dedicated to innovation in rheumatology.

Airway Inflammation Drives Rheumatoid Risk

A cohort analysis of the Nurses' Health Study suggests that asthma and COPD are associated with increased risk for incident rheumatoid arthritis (RA), independent of smoking- thus airway inflammation may be an important factor in the evolution of pre-cllnical RA.

Folate Levels Protect from CV Mortality in RA

In a study of rheumatoid arthritis (RA) patients, JAMA reports that serum folate level of greater than 4.3 ng/mL was associated with lower CV mortality risk.

A cohort study from the third National Health and Nutrition Examination Survey (1988-1994) and 2011 compared assess the risk of CV mortality in 683 RA patients based on their serum folate levels.

Bariatric Surgery Improves Rheumatoid Activity

Obesity is a risk factor for the onset of rheumatoid arthritis (RA) and may also an impediment to optimal DMARD and biologic responses.  A new study has shown that after 1 year, obese RA patients undergoing bariatric surgery with weight loss had significantly lower disease activity.

Seronegativity on the Rise in RA

Although the overall incidence rates of rheumatoid arthritis (RA) have remained stable over recent decades, there has been a significant increase in seronegative cases, a retrospective study showed.